Expression of factor X in both the rat brain and cells of the central nervous system  by Shikamoto, Yasuo & Morita, Takashi
Expression of factor X in both the rat brain and cells of the central
nervous system
Yasuo Shikamoto, Takashi Morita*
Department of Biochemistry, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo 204-8588, Japan
Received 22 September 1999; received in revised form 18 November 1999
Edited by Shozo Yamamoto
Abstract Prothrombin is expressed in the central and periph-
eral nervous systems. However, the mechanism responsible for
the activation of prothrombin to thrombin by the activated form
of factor X in the central and peripheral nervous systems remains
to be explored. Here, we investigated the expression of factor X
mRNA in the brain and some cell lines derived from the central
nervous system. Reverse transcription-polymerase chain reaction
(RT-PCR) demonstrated the expression of mRNA encoding
factor X in the rat brain, A172 (human glioblastoma) and GOTO
(human neuroblastoma) cells. The sequences of PCR-derived
fragments were identical to those reported for rat and human
factor X. These results indicated the synthesis of factor X in the
cells of the central nervous system.
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1. Introduction
Thrombin regulates a number of important biological re-
sponses of cells of the central nervous system (CNS) [1] and
the peripheral nervous system [2]. These cellular reactions oc-
cur at picomolar concentrations of thrombin and are medi-
ated via thrombin receptors and subsequent signaling [3]. Pro-
thrombin is endogenously expressed in the CNS [4], but the
mechanism responsible for prothrombin activation by factor
Xa and the source of the precursor of factor Xa, prothrombin
activator, in the central and peripheral nervous systems has
not been investigated.
Factor X is synthesized in the liver [5] and in the peritoneal
macrophages [6]. Factors X/Xa have also been identi¢ed in
tumor cells and macrophages by immunohistochemical studies
[7]. Northern blotting analysis demonstrated that factor X
mRNA was present in various tissues but not in the brain
[8]. On the other hand, anti-factor X/Xa antibodies stained
factor X/Xa in epithelial cells, macrophages in the white mat-
ter of the brain and brainstem neurons [9]. However, produc-
tion of factor X in cells in the CNS remains to be determined.
Here, we examined the presence of factor X mRNA in the
rat brain and several cell lines derived from CNS cells by RT-
PCR and demonstrated the expression of factor X in both the
brain and cells of the CNS.
2. Materials and methods
2.1. Cell culture
A172 human glioblastoma, GOTO human neuroblastoma, T98G
human glioblastoma, HepG2 human hepatocellular carcinoma and
U373 human astrocytoma cells were cultured in Dulbecco’s modi¢ed
essential medium (DMEM) supplemented with 10% fetal bovine se-
rum (Cell Culture Technologies) and 70 Wg/ml kanamycin. Cultures
were kept in a 5% CO2/95% humidi¢ed air incubator at 37‡C. Cells
were plated on tissue culture dishes (Iwaki Glass, Japan) and passaged
after trypsinization every 5^6 days.
2.2. Animals
Adult Wistar rats were anesthetized by intraperitoneal injection
with barbiturate and perfused with phosphate-bu¡ered saline to re-
move the monocytes and macrophages in the blood. Then, the cere-
brum, cerebellum and liver were dissected out. Tissues were stored in
liquid nitrogen until preparation of RNA.
2.3. RNA preparation
Total RNA was prepared by the standard acid guanidinium iso-
thiocyanate-phenol-chloroform extraction procedure [10] using a kit
(Isogen, Nippon-Gene, Japan). RNA thus obtained was electropho-
resed on 1% agarose gels in the presence of 6% formaldehyde to assess
its purity.
2.4. cDNA preparation and PCR analysis
Oligonucleotide probes were designed based on the published se-
quences of human factor X cDNA [11] and rat factor X cDNA [12]
divided into four and ¢ve regions for optimal ampli¢cation, respec-
tively. For ampli¢cation of human and rat factor X, primers were
obtained commercially (Amersham Pharmacia Biotech). Primers for
the G3PDH gene were utilized as controls (Clontech). Total RNA
(2 Wg) was subjected to cDNA synthesis using oligo (dT)12ÿ18 primer
and AMV reverse transcriptase (Invitrogen) after treatment with
DNase (Nippon-Gene, Japan) and re-extraction of RNA. The
cDNA samples were diluted in a ¢nal volume of 50 Wl. PCR was
carried out in 25-Wl reaction mixtures including 1UPCR bu¡er,
80 WM dNTPs, 0.25 WM of each 5P and 3P primer, 0.5 units of Z-
Taq polymerase (Takara Shuzo, Japan) and 0.5 Wl of synthesized
cDNA using a GeneAmp PCR system 9700 (Perkin Elmer) for
40 cycles of 98‡C for 3 s, 60‡C for 3 s and 72‡C for 5 s. PCR products
were visualized by electrophoresis (2% agarose) and stained with ethi-
dium bromide.
2.5. Sequence of factor X
Ampli¢ed DNA fragments were puri¢ed from agarose gels using
the quick prep DNA puri¢cation system (Bio-Rad). Dideoxy sequenc-
ing of DNA fragments was performed using a DNA Sequencing kit
(Perkin Elmer) and a nucleotide sequencer (model 373A, Applied
Biosystem) to con¢rm their sequences.
2.6. Quantitative reverse transcription PCR
Competitor DNAs £anked by the target gene primer sequences
were constructed using a competitive DNA construction kit (Takara
Shuzo). For ampli¢cation of human factor X transcripts and their
competitors, primers 5P-ACGAGAAGGGCCGGCAGTGTACGGT-
CATCATCTGACAC-3P and 5P-GGAGAGGACGTTATGACCTC-
CGAATACATCAAACGCGCGGAC-3P for human factor X (nu-
cleotides 1103^1457, 355 bp corresponding to serine protease
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region), 5P-CTCACTGCCGCCCATTGTCTCGTACGGTCATCAT-
CTGACAC-3P and 5P-GGCCGTGACCTTCGTGTAGATGCGCG-
TGAGTATTACGAAGGTG-3P for rat factor X (nucleotides 823^
1117, 295 bp corresponding to serine protease region) were used.
Aliquots of 5 Wl of competitor DNAs were coampli¢ed with 0.5^2 Wl
of cDNA under the same conditions as described above. The PCR
products were subjected to electrophoresis in 2% agarose gels and
stained with ethidium bromide. The band intensities were quanti¢ed
using an Electrophoresis Documentation and Analysis system 120
(Kodak) and plotted on logarithmic scales, the x-axis representing
the competitor and the y-axis the ratio of target to competitor (Fig.
3).
3. Results and discussion
RT-PCR analysis was performed to con¢rm the expression
of factor X in A172 (human glioblastoma), GOTO (human
neuroblastoma), T98G (human glioblastoma) and U373 (hu-
man astrocytoma) cells. As a positive control, analysis was
performed with HepG2 (human hepatocellular carcinoma)
cells, which are well known to produce factor X. The expres-
sion of factor X mRNA encoding from the pre-pro to serine
protease region corresponding to the mature protein (Fig. 1)
was detected in A172 and GOTO (data not shown). All PCR
products were of the expected size and were the same as those
ampli¢ed in HepG2. We also analyzed the expression of fac-
tor X mRNA in the rat cerebrum, cerebellum and liver by a
similar method. Signals of factor X were detected from the rat
brain (cerebrum and cerebellum) and liver, and the PCR
products were of the expected sizes (data not shown). Nega-
tive control reactions without reverse transcriptase in the
cDNA synthesis process showed no bands in all experiments,
indicating that there was no contamination by genomic DNA
in the RNA samples.
Next, the sequences of the PCR fragments were analyzed to
con¢rm whether the PCR products were ampli¢ed from factor
X mRNA. DNA sequences obtained from A172 and HepG2
cells were compared over 69% of the ORF of factor X mRNA
and no di¡erences were found. There were no di¡erences in
the ampli¢ed PCR products from rat cerebrum and liver, at
least in the region compared (85.8% of ORF). These results
indicated that A172 human glioblastoma cells and rat brain
express mature factor X mRNA.
To assess the levels of factor X mRNA in the cell lines and
brain, competitive PCR was performed (Fig. 2). GOTO and
A172 cells expressed factor X mRNA at approximately
1U102 and 4U101 copies/reaction (corresponding to 5U103
and 2U103 copies/Wg RNA), respectively (Fig. 3). The expres-
sion level of factor X mRNA was at least 100-fold higher
(1.3U104 copies/reaction, 6.5U105 copies/Wg RNA) in
HepG2 cells. The results of competitive PCR of the control
G3PDH gene quantitatively demonstrated that levels of am-
pli¢ed products were equivalent in all cell lines, con¢rming
that the amounts of cDNA subjected to PCR were the same
in all cell lines.
We also investigated expression of factor X mRNA in the
rat brain with another set of primers (see ‘Quantitative Re-
verse Transcription PCR’) and PCR competitor. Factor X
was expressed in both the cerebrum and cerebellum at
1U102 copies/reaction (5U103 copies/Wg)(Fig. 4). The level
Fig. 1. RT-PCR of human factor X. The starting position of each primer in relation to the mRNA structure is shown above the ¢gure. Primers
were designed to generate PCR products of under 1 kb. Primers 2, 3 and 4 were designed to span an intron in the factor X gene.
Fig. 2. Comparative evaluation of human factor X mRNA for
A172 and GOTO cells by competitive PCR. The mRNA levels of
human factor X (upper) and a housekeeping gene, G3PDH (lower),
were compared between cell lines. (upper) Lanes 1^7 indicate three-
fold serial dilutions of 1U104 copies/reaction of factor X competitor
DNA for A172 and GOTO cells, 1U105 copies/reaction of factor X
competitor for HepG2 cells. (lower) Lanes 1^ 7 indicate three-fold
dilutions of 1U106 copies/reaction of G3PDH control gene for all
cell lines. Competitors were coampli¢ed with constant amounts of
cDNA as described in Section 2.6.
Fig. 3. Data analysis of competitive RT-PCR. The intensity of ethi-
dium bromide-stained DNA bands was quanti¢ed and plotted on
the x-axis, competitor, versus the y-axis, log ratio factor X over
competitor, on a logarithmic scale.
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of factor X mRNA expression in the liver, the primary site of
factor X synthesis, was approximately 1U105 copies/reaction
(5U105 copies/Wg RNA); this level was 1000-fold higher than
those in the cerebrum and cerebellum.
Based on these observations, we examined the expression of
factor X at the mRNA level in the rat brain and human cell
lines by RT-PCR analysis, and con¢rmed the sequence of the
PCR products and competitive PCR. Until the present study,
the expression of factor X in the brain had not been demon-
strated conclusively because of di⁄culty in avoiding serum
contamination. The expression of factor X was not demon-
strated in the brain by a Northern blotting method [8]. How-
ever, we demonstrated the expression of factor X in the brain
and human CNS cell lines using sensitive mRNA detection
methods. This is the ¢rst evidence that factor X mRNA is
expressed in the brain tissue and cultured human cell lines
derived from the CNS. We were not able to identify which
cell type(s) expressed factor X in this study. However, our
preliminary experiments showed that primary cultured astro-
cytes expressed factor X mRNA (unpublished observation).
This implies that the source of factor X in the brain is at least
local synthesis by astrocytes.
Factor X expressed endogenously in the CNS should be a
component of a prothrombin activator. Recently, we showed
that prothrombin is activated to thrombin subsequent to ac-
tivation of factor X in the cells of extravascular regions such
as glial and neural cells by prothrombinase complex [13]. Our
observations suggested that activation of prothrombin on in-
tact cells such as glial and neural cells occurs in response to
nanomolar-order concentrations of factor Xa [13]. Picomolar-
order concentrations of thrombin also cause signi¢cant phys-
iological responses [3]. The optimal concentration of thrombin
to cause the biological reaction in CNS cells via the thrombin
receptor is far lower than that for ¢brin conversion in plasma.
This could induce the activation of prothrombin by factor Xa,
produced in the CNS, even if the level of factor X transcript
expression in the brain (cerebrum and cerebellum) is 100^
1000-fold lower than that in hepatic cells. The optimal con-
centration of thrombin to cause the biological reaction in
CNS cells via the thrombin receptor appears to be entirely
di¡erent from that for ¢brin conversion in plasma.
Prothrombin is physiologically activated to thrombin by a
prothrombinase complex consisting of factor Xa, factor Va,
Ca2 and a phospholipid-containing surface. Together the
constituents of prothrombinase enhance the factor Xa-medi-
ated activation of prothrombin to thrombin by ¢ve orders of
magnitude. Factor V(a) may also participate in the composi-
tion of prothrombinase complex in the CNS, although it has
not been con¢rmed that factor V is present in the CNS. Hu-
man brain pericytes expressed e¡ector cell protease receptor-1
(EPR-1) and propagated blood coagulation including the ex-
trinsic pathway [14]. Thus, EPR-1 might contribute to the
molecular assembly of the components of prothrombinase
on CNS cells.
Alternative cleavage of factor X by plasmin and its ¢nal
products was also reported to inhibit blood coagulation [15],
suggesting that plasmin is a regulator of the function of factor
X. Factor X in the brain may participate in ¢brinolysis or
have other as yet unknown functions when plasmin is ex-
pressed in the brain.
Acknowledgements: We are grateful to Dr. Yongchol Shin for his
helpful suggestions. We would also like to thank Yusuke Takahashi,
Takayoshi Ashie, Yukako Shimano and Satsuki Hori for technical
assistance. This work was supported by a Research Grant for Car-
diovascular Diseases (8A-1) from the Ministry of Health and Welfare
to T. Morita.
References
[1] Gurwitz, D. and Cunningham, D.D. (1988) Proc. Natl. Acad.
Sci. USA 85, 3440^3444.
[2] Zoubine, M.N., Ma, J.Y., Smirnova, I.V., Citron, B.A. and Fest-
o¡, B.W. (1996) Dev. Biol. 179, 447^457.
[3] Donovan, F.M. and Cunningham, D.D. (1998) J. Biol. Chem.
273, 12746^12752.
[4] Dihanich, M., Kaser, M., Reinhard, E., Cunningham, D. and
Monard, D. (1991) Neuron 6, 575^581.
[5] Shaw, E., Giddings, J.C., Peake, I.R. and Bloom, A.L. (1979) Br.
J. Haematol. 41, 585^596.
[6] Lindahl, U., Kolset, S.O., Bogwald, J., Osterud, B. and Seljelid,
R. (1982) Biochem. J. 206, 231^237.
[7] Zacharski, L.R., Dunwiddie, C., Nutt, E.M., Hunt, J. and Mem-
oli, V.A. (1991) Thromb. Haemost. 65, 545^548.
[8] Hung, H.L. and High, K.A. (1996) J. Biol. Chem. 271, 2323^
2331.
[9] Yamada, T. and Nagai, Y. (1996) Histochem. J. 28, 73^77.
[10] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156^
159.
[11] Messier, T.L., Pittman, D.D., Long, G.L., Kaufman, R.J. and
Church, W.R. (1991) Gene 99, 291^294.
[12] Stanton, C., Ross, P., Hutson, S. and Wallin, R. (1995) Thromb.
Res. 80, 63^73.
[13] Yamazaki, Y., Shikamoto, Y., Fukudome, K., Kimoto, M. and
Morita, T. (1999) J. Biochem. (Tokyo) 126, 655^661.
[14] Bouchard, B.A., Shatos, M.A. and Tracy, P.B. (1997) Arterio-
scler. Thromb. Vasc. Biol. 17, 1^9.
[15] Pryzdial, E.L., Lavigne, N., Dupuis, N. and Kessler, G.E. (1999)
J. Biol. Chem. 274, 8500^8505.
Fig. 4. Comparative evaluation of rat factor X mRNA for the cere-
brum and cerebellum by competitive PCR. Experiments similar to
those described in Fig. 2 were performed. The mRNA levels of rat
factor X (upper) and a housekeeping gene, G3PDH (lower), were
compared between cell lines. (upper) Lanes 1^7 indicate ¢ve-fold se-
rial dilutions of 1U104 copies/reaction of rat factor X competitor
DNA for cerebrum and cerebellum, 1U106 copies/reaction of factor
X competitor for liver. (lower) Lanes 1^7 indicate three-fold dilu-
tions of 3U105 copies/reaction of G3PDH control gene for tissues.
Competitors were coampli¢ed with constant amounts of cDNA as
described in Section 2.6.
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